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Components of normal serum block the focal segmental glo- progression to renal failure. It accounts for end-stage
merulosclerosis factor activity in vitro. renal disease in many children and adults [1–8]. The
Background. Sera from some patients with focal segmental observations that FSGS recurs in 30% of renal allografts,glomerulosclerosis (FSGS) increase glomerular albumin per-
that proteinuria may begin within hours after trans-meability (Palb) in vitro. The hypothesis that a component of
plantation, and that treatment with plasmapheresis cannormal serum can protect the glomerular permeability barrier
was tested using sera from FSGS patients, normal individuals, reduce proteinuria and stabilize renal function implicate
and several mammalian and avian species. a circulating factor as an etiologic agent in FSGS [9–11].
Methods. In most experiments, isolated rat glomeruli were We have shown that sera from some patients with FSGSincubated in medium containing FSGS serum known to in-
increase albumin permeability (Palb) of isolated glomerulicrease Palb in vitro, normal serum, or both active FSGS and
in vitro, have isolated and partially purified this factornormal serum. In other experiments, fractions of normal serum
and serum from other vertebrate species were incubated with (FSGS factor), and have shown that the FSGS factor
active FSGS serum. Palb was calculated from glomerular capil- causes proteinuria in rats [12, 13]. Permeability activity
lary expansion in response to an oncotic gradient. To enrich has been confirmed by others [14, 15] and may predictthe blocking activity, normal pooled human plasma was sub-
recurrence [16, 17].jected to various biochemical manipulations.
Our initial observations of increased Palb caused byResults. Normal human serum prevented the increase in Palb
(active FSGS sera, 0.77 6 0.12; active FSGS sera:normal serum, FSGS factor led us to hypothesize that proteinuria might
1:1 mix, 0.06 6 0.30, P , 0.001). Protection diminished as be related to a deficiency of a protective substance in
the concentration of normal serum was decreased. Specific
addition to the presence of an injurious one. The experi-fractions of human serum, including human albumin and immu-
ments described here address that hypothesis and havenoglobulin fractions, were not protective. Blocking activity was
present in 80% ammonium sulfate precipitate and certain frac- been carried out during the past 10 years concurrently
tions from size-exclusion chromatography of normal pooled with isolation of the FSGS factor.
human plasma. Normal serum from each of the vertebrate
species tested also prevented the increase in Palb. Preincubation
with normal serum was protective during subsequent incuba- METHODS
tion with FSGS serum, but normal serum was not protective
Determination of albumin permeabilityafter preincubation with FSGS serum.
Conclusions. We conclude that a factor or factors in normal Normal male Sprague-Dawley rats (120 to 150 g)
serum block the permeability effect of active FSGS sera. This maintained on rat chow and water ad libitum were usedphenomenon may account for variability in proteinuria among
for all experiments. Kidneys were removed, and glomer-patients with FSGS and may explain inconsistent proteinuria
uli were isolated in an isolation/incubation medium con-following injection of FSGS sera into experimental animals.
Characterization of the protective substance(s) and the mecha- taining 4% bovine serum albumin (BSA) as an oncotic
nism by which the increase in permeability is blocked may agent using standard sieving techniques. In most experi-
provide insight into the pathogenesis of FSGS.
ments, glomeruli were then incubated with FSGS serum
with or without normal serum or fractions for 10 minutes
Focal segmental glomerulosclerosis (FSGS) is charac- at 378C. In some studies, glomeruli were preincubated
terized by nephrotic syndrome and a high incidence of at 48C for 10 minutes with normal serum or FSGS serum.
An oncotic gradient across the glomerular capillary was
produced by replacing the incubation medium with me-Key words: proteinuria, glomerular albumin permeability, nephrotic
syndrome, filtration barrier, sclerosis, renal disease progression. dium containing 1% BSA. Changes in glomerular vol-
ume consequent to this change of medium reflectedReceived for publication March 10, 2000
expansion of glomerular capillaries and were recordedand in revised form May 22, 2000
Accepted for publication May 26, 2000 using videomicroscopy. Glomerular volume was calcu-
lated from the average diameter of the video image.Ó 2000 by the International Society of Nephrology
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Relative volume change (DV) was calculated as DV 5 ammonium sulfate saturation and the precipitate at 80%
ammonium sulfate saturation were tested for blocking(VFinal 2 VInitial)/VInitial 3 100%. As previously described,
the ratio of DVExperimental/DVControl was used to calculate activity. Some of the 80% precipitate of normal plasma
was subjected to size exclusion chromatography usingthe albumin reflection coefficient (salb) and convectional
permeability (Palb) where Palb 5 (1 2 salb) [18]. Sephacryl S-300 matrix. Fractions of 1.5 mL size were
collected and tested for blocking activity upon addition
Determination of blocking activity to the 80% precipitate of FSGS serum and the size exclu-
sion (Sephacryl S-300) fraction of FSGS serum.To determine whether normal serum affects the in-
crease in Palb caused by the FSGS factor, studies were
Electrophoresiscarried out using sera from FSGS patients, with active
plasmapheresis fluid or fractions thereof; in each case, The 80% precipitates of active FSGS plasma and of
normal human plasma were prepared as described ear-the substance tested had Palb . 0.5. Normal serum was
obtained from volunteers without known medical disease lier [10]. Aliquots of these two preparations containing
equal amounts of protein and of a solution containing aand was used individually or after pooling with two or
more specimens. Additional studies were performed us- 1:1 mix of each were subjected to electrophoresis under
nondenaturing, nonreducing conditions (native condi-ing serum of other species or fractions of human serum.
In initial studies, glomeruli were incubated with serum tions) using 4 to 20% gradient gels in Tris-glycine buffer.
of individual FSGS patients, with serum from normal
Statistical analysisvolunteers, or with a mixture of normal human serum
and serum from FSGS patients. The amount of each test Albumin permeability values are expressed as mean 6
SD of the mean as indicated. N represents the totalsubstance added was 2% vol/vol. Details of the protocols
are described with results of individual experiments. number of glomeruli for Palb studies. Values among vari-
ous groups were compared using Student’s t-test or one-
Chemicals and supplies way analysis of variance (ANOVA), and significance was
Lyophilized powder of pooled serum from normal defined as P , 0.05.
sheep, chicken, calf, mouse, cat, pig, duck, goat, or horse
(Sigma Chemical Company, St. Louis, MO, USA) were
RESULTSreconstituted with sterile water. Fresh human and rat
Glomeruli were incubated with 2% vol/vol of normalsera were prepared from whole blood. Purified human
human serum, with active sera from one of four patientsalbumin and immunoglobulin fractions (Sigma Chemical
with FSGS in native kidneys or recurrence in renal allo-Co.) were also tested. Additionally, larger amounts of
graft or a 1:1 mixture of individual FSGS and normalnormal human plasma were obtained from healthy vol-
sera. Incubation with normal serum alone (0.2 6 0.1)unteers or from a local blood bank (The Blood Center
did not alter Palb values compared with medium withoutof Southeastern Wisconsin, Milwaukee, WI, USA). BSA
serum (0 6 0.08). Incubation with each FSGS serum(35% solution), high-pressure liquid chromatography
significantly increased Palb. In each case, the increase in(HPLC) grade solvents, analytical grade chemicals for
Palb was prevented by the inclusion of normal serum. Thebuffers, and other reagents (Sigma), and Spectra-pore
characteristics of the patients studied and the results ofdialysis tubing (Spectrum Medical Industries, Inc., La-
incubation with their sera and with FSGS and normalguna Hills, CA, USA) were used.
serum are shown in Table 1. The effect of incubation
Enrichment of blocking activity with combined normal serum and negative FSGS patient
serum, defined by failure to increase Palb to more thanNormal pooled plasma was treated to remove cryopre-
0.5, was also studied. In these experiments, Palb was notcipitate, lipoproteins and chylomicrons, and protein frac-
altered by normal, negative FSGS, or combined serations that are known to be rich in immunoglobulins and
(data not shown).albumin using the same chemical manipulations as de-
To determine whether the blocking effect of normalscribed earlier for enrichment of FSGS activity [10].
serum was species specific, serum from several vertebrateThese steps are outlined briefly as follows: Plasma was
species was tested. In these experiments, serum fromfrozen and allowed to thaw at 48C; cryoprecipitate was
various species and FSGS serum were each added atdiscarded. Protein-bound lipids were removed by the
concentrations of 2% vol/vol. Serum from all speciesaddition of 10% dextran sulfate and 1 mol/L calcium
tested prevented the increase in Palb caused by FSGSchloride. The resulting precipitate of lipoproteins and
serum. These results are shown in Table 2.chylomicrons was removed by centrifugation at 48C and
To determine the concentration of normal human se-was discarded. The remaining plasma components were
rum required to prevent the increase in Palb caused bysubjected to sequential ammonium sulfate precipitation
at 50, 70, and 80% saturation. The supernatant at 70% FSGS serum, we added normal serum in concentrations
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Table 1. Effect of normal sera on the increase in glomerular albumin permeability (Palb)
caused by focal segmental glomerulosclerosis (FSGS) sera
PalbPatient
number Primary/recurrent Gender Age years FSGS FSGS 1 normal
1a, sf9091 Recurrent M 30 0.7060.05 (5) 0.0360.05 (5)a
1b, sf171 0.8560.14 (5) 0.2460.20 (5)a
2, sf33 Primary F 42 0.8060.06 (5) 0.0360.31 (5)a
3, sf95 Recurrent M 48 0.6460.26 (5) 0.0060.47 (5)a
4, sf215 Primary F 16 0.8660.08 (5) 0.0160.50 (5)a
Average Palb 0.7760.12 (25) 0.0660.30 (25)a
Five active serum samples from four patients were tested for their capacity to increase Palb of isolated glomeruli. Two patients had primary FSGS, two recurrent
FSGS after renal transplantation as indicated. Values for Palb are expressed as mean 6 standard deviation with (N ) equal to the number of glomeruli studied.
a Different from FSGS serum alone, P , 0.01
Table 2. Effect of serum from vertebrate species on the FSGS
serum mediated increase in Palb
Albumin permeability
Source of serum N (Palb)
Sera from fresh blood
None (FSGS patient only) 26 0.6260.18











Duck 5 0.0560.07a Fig. 1. Dose response of the blocking effect of normal serum on focal
segmental glomerulosclerosis (FSGS) serum-mediated increase in glo-Isolated rat glomeruli were incubated in medium containing active FSGS
merular albumin permeability (Palb). Relative concentration of normalserum with or without a 1:1 mix of serum from vertebrate species and Palb was
to FSGS serum of at least 1:1 is required to prevent increased Palb.calculated. Serum from each species tested prevented the increase in Palb caused
Values for Palb are expressed as mean 6 SD. The asterisk indicatesby FSGS serum. Values for Palb are expressed as mean 6 standard deviation
with N 5 number of glomeruli. different from glomeruli incubated with FSGS serum alone at P ,
a P , 0.001, bP , 0.02, vs. FSGS serum alone 0.001.
served as negative and positive controls, respectively.of 10, 2, 1, 0.5, and 0.1% vol/vol to medium containing
2% FSGS serum. Inclusion of 10 or 2% normal serum, Preincubation with normal serum protected glomeruli
from increased Palb caused by FSGS serum in subsequentcorresponding to relative concentrations of normal to
FSGS serum of 5:1 and 1:1, respectively, completely pre- incubation. In contrast, incubation of glomeruli with nor-
mal serum after preincubation with FSGS serum did notvented the increase in Palb, while lower concentrations
(relative concentrations of 0.5:1, 0.25:1, and 0.1:1) were protect the glomeruli from the increase in Palb caused by
FSGS serum. Results of a typical experiment are shownnot protective. These results are illustrated in Figure 1.
Studies were performed to determine whether the si- in Figure 2.
To enrich the blocking activity, normal pooled humanmultaneous presence of normal and FSGS sera is neces-
sary to prevent the increase in Palb. In these studies, plasma was subjected to various biochemical manipula-
tions, as outlined previously [12] and in the Methods sec-glomeruli were preincubated with normal human serum
for 10 minutes at 48C followed by washing and subse- tion. Plasma retained its blocking activity after removal
of cryoprecipitate, lipoproteins, and proteins precipitatedquent incubation with FSGS serum from patients with
recurrent disease for 10 minutes at 378C. In another at 50 and 70% of ammonium sulfate saturation. Blocking
activity was present in both the supernatant at 70% satu-group, glomeruli were preincubated with the same FSGS
serum for 10 minutes at 48C followed by washing and ration and in the 80% precipitate. In contrast, blocking
activity was not found in commercially prepared albuminsubsequent incubation with normal serum for 10 minutes
at 378C. Additional glomeruli were also incubated either or in immunoglobulin fractions. The results of experi-
ments using plasma fractions are displayed in Table 3.with normal serum or with FSGS serum throughout and
Sharma et al: FSGS blocking factor in normal serum1976
Fig. 2. Effect of sequential incubation with normal and FSGS serum
on Palb. Preincubation of isolated rat glomeruli with normal serum is
required to protect them from the increase in Palb caused by FSGS
serum. Values for Palb are expressed as mean 6 SD. The asterisk indi-
cates different from glomeruli incubated with normal serum alone or
preincubated with normal serum prior to incubation with FSGS at P ,
0.001.
Table 3. Effect of various fractions of normal
plasma on FSGS activity
Albumin permeability (Palb)Fractions of normal
plasma tested FSGS alone FSGS 1 normal fraction
Human albumin 0.7660.05 (5), sf54 0.8060.16 (5)
Immunoglobulin 0.7660.05 (5), sf54 0.7360.15 (5)
80% precipitate 0.6760.07 (5), sf106 0.1060.23a (5)
Isolated glomeruli were incubated with active FSGS sera (sf54 and 106) alone
(2% vol/vol) or with purified human albumin fraction (5% vol/vol), immunoglob-
ulin fraction (5% vol/vol) and with 80% precipitate of normal human plasma
(2% vol/vol). FSGS sera mediated increase in Palb was blocked only by 80% ppt Fig. 3. Electrophoretic pattern of proteins in the enriched fractions
of normal pooled plasma. Values depicted for Palb are mean 6 standard deviation of normal, FSGS, and a 1:1 mix of normal with FSGS plasma. Gelwith (N) 5 number of glomeruli.
electrophoresis was performed under nondenaturing and nonreducinga P , 0.004, significant differences from Palb with FSGS serum alone
conditions, and proteins were stained using silver staining. Lane 1, 80%
precipitate of normal plasma. Lane 2, 80% precipitate of FSGS plasma.
Lane 3, a 1:1 mix of 80% precipitate of FSGS and normal plasma.
The 80% precipitate of normal human plasma, 80%
precipitate of plasma from a patient with recurrent
80% precipitate were tested for blocking activity by incu-FSGS, or a 1:1 mixture of the two were studied for their
protein profile by gel electrophoresis under nondenatur- bating glomeruli with a 1:1 mix of each normal fraction
ing, nonreducing conditions. Equal amounts of protein and an active FSGS fraction 20. Only normal fraction
(100 ng) were loaded in each lane. As shown in Figure 20 blocked the increase in Palb caused by fraction 20 of
3 and marked by an arrow, a prominent band is seen in FSGS (active fraction, 0.53 6 0.21, N 5 8; active FSGS 1
the lane 2 (FSGS 80% precipitate). This band is less normal fraction, 1:1 mix, 0.18 6 0.08, N 5 8; P , 0.001).
prominent in lane 1 (normal 80% precipitate) and is not Normal fraction 20 alone had no effect on Palb (0.19 6
evident in the lane 3 (1:1 mixture of FSGS 80% and 0.10, N 5 8). Thus, fractionation of normal plasma re-
normal 80% precipitate). vealed that the blocking activity was retained in the same
Active 80% precipitate from a patient with recurrent fractions that carried the FSGS factor.
FSGS and an aliquot of 80% precipitate of normal
plasma with blocking activity was dissolved in phosphate-
DISCUSSIONbuffered saline and passed through a Sephacryl S-300 size-
In the current studies, we confirmed our previous ob-exclusion column chromatography. Fractions of 1.5 mL
servations that sera from selected patients with FSGSwere collected. All fractions of FSGS were tested for
either in native kidneys or after transplantation have thePalb activity, and fractions 20 and 21 showed positive
activity (0.53 6 0.21, N 5 8). All fractions of normal capacity to increase glomerular Palb in vitro. We also
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document that the increase in glomerular Palb by FSGS nale for the calculation of Palb have been detailed pre-
viously [18].sera is prevented by one or more components of normal
serum. Protection is conferred by both individual human Our Palb assay demonstrates the effects of several ex-
perimental interventions on the glomerular permeabilitysera and pooled serum. In addition, plasma of each of
the vertebrate species tested also prevented the FSGS- barrier. Findings include documentation that (1) the
C5b-9 membrane attack complex is essential to the im-induced increase in Palb.
The blocking effect depends on the concentration of mediate permeability increase induced by anti-Fx1A
[19]; (2) antibodies to b1 integrin increase permeabilityserum used and is maximal when a concentration equal
to or in excess of the concentration of FSGS serum is independent of complement [20]; (3) superoxide [21]
or hydroxyl ions [22] increase permeability; (4) tumorused. Thus, under our standard conditions of 2% FSGS
serum, 2% or higher concentrations of normal serum necrosis factor-a [23] or transforming growth factor-b1
[24] increase permeability through superoxide; and (5)were required. We found that the protective factor or
factors need not be present in solution simultaneously charge neutralization by protamine [18], prolonged incu-
bation with platelet-activating factor [25], or enzymaticwith the FSGS factor to exert the protective effect. Spe-
cifically, preincubation with normal serum followed by degradation of basement membrane by matrix metallo-
proteinase-3 [26] each increase permeability. In addition,washing and subsequent incubation with FSGS serum
provided complete protection, while preincubation with we have used the assay to permit us to follow the perme-
ability activity of FSGS sera through a series of biochemi-FSGS serum followed by washing and incubation with
normal serum still resulted in an increase in Palb. We cal steps to achieve partial purification of the FSGS fac-
tor [12].believe that competition between the FSGS factor and
normal components for binding sites on glomerular cells We have previously shown that sera of about 30% of
patients with FSGS increase Palb to a value of greateris the most likely explanation for our findings. However,
other mechanisms, including binding of a component of than 0.5. Activity is enriched in fractions of plasma, spe-
cifically in 70% ammonium sulfate supernatant and pre-normal serum to the FSGS factor or enzymatic degrada-
tion of the FSGS factor by a component of normal cipitate at 80% ammonium sulfate saturation. An injec-
tion of 70% supernatant results in transient proteinuriaplasma, cannot be excluded.
Protection was present both in intact serum or plasma in rats [12]. These findings are consistent with the reports
of proteinuria after injection of patients’ plasma [27] andand in specific plasma fractions. Blocking activity was
retained during ammonium sulfate fractionation that re- certain plasma fractions eluted from protein-A column
[13]. Seventy percent supernatant also inhibits inductionmoves the majority of albumin and immunoglobulins
and was not present in commercially available purified of nitric oxide synthase (iNOS) in cultured rat mesangial
cells [28] and thus confirms the presence of a substancehuman albumin or immunoglobulin fractions. The pro-
tective component of normal serum was present in the that directly affects the function of glomerular cells.
The current findings that normal serum blocks thesize-exclusion chromatography fraction analogous to
that which contained the FSGS factor. These observa- effect of FSGS serum on Palb and that this effect is abol-
ished if the ratio of FSGS to normal serum is highlytions support the notion that the substance responsible
for blocking permeability activity shares some biochemi- supportive of the notion that a relatively large quantity
of FSGS factor is required to overcome protective capa-cal characteristics with the FSGS factor itself.
The assay for glomerular albumin permeability has bility of plasma. The inconsistent results of injection of
sera from FSGS patients may reflect the use of insuffi-been developed and standardized in our laboratory dur-
ing the past 12 years. Isolated glomeruli are observed as cient amounts of FSGS factor to overcome this protec-
tion. The mechanism for protection is not clear from theisolation medium is replaced by medium of lower oncotic
concentration. Under constant experimental conditions, current experiments. We propose that the normal serum
component and FSGS factor interact independently withthe resulting expansion of capillaries and increase in
glomerular size are proportional to the reflection coeffi- glomerular cells. This interpretation is supported by our
findings that sequential incubation with normal andcient of albumin (salb). For convenience, we have calcu-
lated convectional albumin permeability, Palb, as (1 2 FSGS sera results in maintenance of the filtration barrier,
while initial exposure to FSGS serum followed by normalsalb). Alternative causes for diminished capillary disten-
tion, including altered exchangeable volume caused by serum results in increased Palb. Alternatively, it is possible
that normal serum contains a component that binds tocell swelling and diminished capillary compliance, have
been excluded using solutions of high molecular weight or enzymatically degrades the FSGS factor. The disap-
pearance of a band on the gel electrophoresis of nonde-solutes such as dextran. Capillary responses to these
gradients assure that alterations in volumetric responses natured proteins from comparable fractions of FSGS and
normal plasma supports this hypothesis.to an albumin gradient are due to a change in permeabil-
ity rather than other changes. The calculations and ratio- The fact that the physiologic response of glomeruli to
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9. Artero M, Sharma R, Savin VJ, Vincenti F: Plasmapheresis re-FSGS factor is prevented by the blocking factor in nor-
duces proteinuria and serum capacity to injury glomeruli in patientsmal serum is not unique in that we have shown that with recurrent focal glomerulosclerosis. Am J Kidney Dis 23:574–
cyclosporine A [29], indomethacin (abstract; McCarthy 581, 1994
10. Feld SM, Figueroa P, Savin V, Nast CC, Sharma R, Sharma M,et al, J Am Soc Nephrol 7:2465, 1996), or derivatives of
Hirschberg R: Plasmapheresis in the treatment of steroid-resistantTripterigium wilfordii [30] each prevent the increase in
focal and segmental glomerulosclerosis in native kidneys. Am JPalb caused by the FSGS factor. Since the protection Kidney Dis 32:230–237, 1998
occurs in the absence of perfusion, we postulate that 11. Dantal J, Godfrin Y, Soulillou JP: New insight into the patho-
these agents prevent the increase in Palb by acting on the genesis of the “idiopathic nephrotic syndrome.” Nephrol Dial
Transplant 10:1979–1982, 1995cells of the filtration barrier. We further propose that a
12. Sharma M, Sharma R, McCarthy ET, Savin VJ: ‘The FSGS fac-component(s) of normal plasma also prevents changes
tor:’ Enrichment and in vivo effect of activity from focal segmental
in glomerular permeability through action on glomerular glomerulosclerosis plasma. J Am Soc Nephrol 10:552–561, 1999
cells. 13. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, de
Hurault Ligny B, Niaudet P, Charpentier B, Soulillou JP:In summary, the final effect of the FSGS factor on
Effect of plasma protein adsorption on protein excretion in kidneyglomerular filtration may reflect the net influence of the
transplant recipients with recurrent nephrotic syndrome. N Engl
FSGS factor and of protective substances found in J Med 330:7–14, 1994
plasma. The identification and characterization of the 14. Godfrin Y, Dantal J, Bouhours JF, Heslan JM, Soulillou JP:
A new method of measuring albumin permeability in isolatedFSGS factor and of protective factors will be essential
glomeruli. Kidney Int 50:1352–1357, 1996to understand fully the events leading to proteinuria and
15. Godfrin Y, Dantal J, Perretto S, Hristea D, Legendre C, Kreissclerosis in FSGS and other progressive renal diseases. H, Soulillou JP: Study of the in vitro effect on glomerular albumin
permselectivity of serum before and after renal transplantation in
focal segmental glomerulosclerosis. Transplantation 64:1711–1715,ACKNOWLEDGMENTS
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